Treatment outcomes of advanced hepatocellular carcinoma in real-life practice: Chemotherapy versus multikinase inhibitors.
Songporn OranratnachaiSasivimol RattanasiriEkaphop SirachainanAmarit TansawetNilubol RaunroadroongGareth J McKayJohn AttiaAmmarin ThakkinstianPublished in: Cancer medicine (2022)
Despite significantly shorter median OS and PFS than Sorafenib, FOLFOX still extended OS by 8.22 months. This evidence may offer clinical utility to physicians considering treatment options for aHCC in low resource settings.